Michael Clark

Metabometrix Ltd. provides metabonomics research services. It uses nuclear magnetic resonance technology to generate and interpret high-density metabolic data using robotic flow-injection technology. The firm markets its metabonomic technologies to pharmaceutical and biotechnology companies. Metabometrix was founded by Jeremy Kirk Nicholson in 2000 and is headquartered in London, the United Kingdom.

Metabometrix Ltd. provides metabonomics research services. It uses nuclear magnetic resonance technology to generate and interpret high-density metabolic data using robotic flow-injection technology. The firm markets its metabonomic technologies to pharmaceutical and biotechnology companies. Metabometrix was founded by Jeremy Kirk Nicholson in 2000 and is headquartered in London, the United Kingdom.

Metabometrix Ltd. provides metabonomics research services. It uses nuclear magnetic resonance technology to generate and interpret high-density metabolic data using robotic flow-injection technology. The firm markets its metabonomic technologies to pharmaceutical and biotechnology companies. Metabometrix was founded by Jeremy Kirk Nicholson in 2000 and is headquartered in London, the United Kingdom.

Metabometrix Ltd. provides metabonomics research services. It uses nuclear magnetic resonance technology to generate and interpret high-density metabolic data using robotic flow-injection technology. The firm markets its metabonomic technologies to pharmaceutical and biotechnology companies. Metabometrix was founded by Jeremy Kirk Nicholson in 2000 and is headquartered in London, the United Kingdom.

Metabometrix Ltd. provides metabonomics research services. It uses nuclear magnetic resonance technology to generate and interpret high-density metabolic data using robotic flow-injection technology. The firm markets its metabonomic technologies to pharmaceutical and biotechnology companies. Metabometrix was founded by Jeremy Kirk Nicholson in 2000 and is headquartered in London, the United Kingdom.